Bristol Myers to Acquire the Drugmaker Karuna for $14 Billion
Bristol Myers Squibb, the global pharmaceutical giant, said on Friday that it would acquire Karuna Therapeutics, which makes drugs to treat schizophrenia and Alzheimer’s, in an all-cash deal valued at $14 billion as it looks to strengthen its pipeline of neuroscience drugs.Bristol Myers said in a statement that it would pay $330 per share in cash, a premium of roughly 53 percent to Karuna’s share price on Thursday.An increasing prevalence of schizophrenia, driven in part by an aging population, has led to a push to make more drugs to treat it. The market for such therapies is estimated to grow to $12.6 billion by 2032, according to the research firm Market.Us. Earlier this month, the biomedical company AbbVie bought Cerevel Therapeutics, which develops drugs to treat psychiatric and neurol...